Literature DB >> 28446126

CD44 silencing decreases the expression of stem cell-related factors induced by transforming growth factor β1 and tumor necrosis factor α in lung cancer: Preliminary findings.

Fariz Nurwidya1, Fumiyuki Takahashi, Motoyasu Kato, Hario Baskoro, Moulid Hidayat, Aditya Wirawan, Kazuhisa Takahashi.   

Abstract

The mechanism underlying increased concentrations of cancer stem cell (CSC)-associated factors in non-small cell lung cancer (NSCLC) cells treated with transforming growth factor β1 (TGFβ1) and tumor necrosis factor α (TNFα), is still not clear. The purpose of this study was to investigate the possible role of CD44 in the regulation of CSC-associated genes, by analyzing the effect of CD44 knockdown on their expression. A549, a NSCLC cell line that expresses CD44 antigen, was treated with TGFβ1 and TNFα. Small-interfering ribonucleic acid (siRNA) that specifically targets the CD44 gene was used to knockdown the expression of CD44 in A549. The gene expressions of CD44, CXCR4, POU5F1 (octamer-binding transcription factor 4 [Oct4]), PROM1, NANOG, c-Myc, KLF4, and SOX2, as well as of CDH1 (E-cadherin), CDH2 (N-cadherin), VIM (vimentin), and FN1 (fibronectin) were analyzed in A549 cells by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Cell morphology was observed using light microscopy. After TGFβ1/TNFα treatment, increased expressions of CXCR4 and POU5F1 were detected. Silencing of CD44 gene expression was confirmed by RT-qPCR. The knockdown of CD44 decreased the CXCR4 and POU5F1 gene expressions in TGFβ1/TNFα-treated A549 cells. However, the silencing of CD44 did not affect the morphology of TGFβ1/TNFα-treated A549 cells nor it reversed epithelial-mesenchymal transition (EMT) gene signature induced by TGFβ1/TNFα in A549 cells. Our preliminary findings suggest that the CD44 gene may have a role in regulating CXCR4 and POU5F1 gene expressions, independently of the EMT signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28446126      PMCID: PMC5581971          DOI: 10.17305/bjbms.2017.1966

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  25 in total

Review 1.  Lung cancer stem cells: tumor biology and clinical implications.

Authors:  Fariz Nurwidya; Akiko Murakami; Fumiyuki Takahashi; Kazuhisa Takahashi
Journal:  Asia Pac J Clin Oncol       Date:  2012-05-21       Impact factor: 2.601

2.  CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Kosuke Mima; Hirohisa Okabe; Takatsugu Ishimoto; Hiromitsu Hayashi; Shigeki Nakagawa; Hideyuki Kuroki; Masayuki Watanabe; Toru Beppu; Mayumi Tamada; Osamu Nagano; Hideyuki Saya; Hideo Baba
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

Review 3.  Perspectives of CD44 targeting therapies.

Authors:  V Orian-Rousseau; H Ponta
Journal:  Arch Toxicol       Date:  2014-12-05       Impact factor: 5.153

4.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.

Authors:  R E Eliaz; F C Szoka
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

5.  Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity.

Authors:  Kazuhisa Takahashi; Fumiyuki Takahashi; Michihiro Hirama; Kenneth K Tanabe; Yoshinosuke Fukuchi
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

6.  Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Authors:  Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Clin Cancer Res       Date:  2013-09-13       Impact factor: 12.531

7.  Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.

Authors:  Elaine Lai-Han Leung; Ronald R Fiscus; James W Tung; Vicky Pui-Chi Tin; Lik Cheung Cheng; Alan Dart-Loon Sihoe; Louis M Fink; Yupo Ma; Maria Pik Wong
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

8.  Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.

Authors:  Akiko Murakami; Fumiyuki Takahashi; Fariz Nurwidya; Isao Kobayashi; Kunihiko Minakata; Muneaki Hashimoto; Takeshi Nara; Motoyasu Kato; Ken Tajima; Naoko Shimada; Shin-ichiro Iwakami; Mariko Moriyama; Hiroyuki Moriyama; Fumiaki Koizumi; Kazuhisa Takahashi
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

9.  Generation of human induced pluripotent stem (Ips) cells in serum- and feeder-free defined culture and TGF-Β1 regulation of pluripotency.

Authors:  Sachiko Yamasaki; Yuki Taguchi; Akira Shimamoto; Hanae Mukasa; Hidetoshi Tahara; Tetsuji Okamoto
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

10.  Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma.

Authors:  Yukari Asai-Tajiri; Koichiro Matsumoto; Satoru Fukuyama; Keiko Kan-O; Takako Nakano; Ken Tonai; Tatsukuni Ohno; Miyuki Azuma; Hiromasa Inoue; Yoichi Nakanishi
Journal:  Respir Res       Date:  2014-10-27
View more
  1 in total

1.  HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.

Authors:  Yuzhou Shen; Wentao Li
Journal:  Drug Des Devel Ther       Date:  2018-07-23       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.